Dr Arvo Rosenthal OÜ
- Address
- lock Available on a paid plan
Dr Arvo Rosenthal OÜ - Cardiovascular and Lipid Disorders Research
Dr Arvo Rosenthal OÜ is a clinical research center specializing in cardiovascular medicine and lipid metabolism disorders. The center focuses on investigating novel therapeutic approaches for patients with hypercholesterolemia and atherosclerotic cardiovascular disease (ASCVD), contributing to the advancement of preventive cardiology and lipid-lowering treatment strategies.
- Lipid-lowering therapies and LDL-cholesterol management in high-risk cardiovascular patients
- Prevention of major adverse cardiovascular events (MACE) including cardiovascular death, myocardial infarction, and stroke
- Novel pharmacological interventions such as inclisiran for atherosclerotic cardiovascular disease
The center's research portfolio emphasizes the evaluation of innovative medications designed to reduce LDL-cholesterol levels and improve cardiovascular outcomes in patients with established vascular disease. By conducting placebo-controlled trials, Dr Arvo Rosenthal OÜ contributes valuable evidence on the efficacy and safety of emerging treatments that aim to help patients achieve individual cholesterol targets and reduce the risk of life-threatening cardiovascular events.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 44 other sites in Estonia
Therapeutic Area Benchmark — Estonia
Select a therapeutic area to compare against other sites in Estonia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Estonia
Market Share
Country: Estonia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Dr Arvo Rosenthal OÜ
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active-Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation | Janssen Cilag International | Phase III | Not Recruiting | Aug 2023 | — |
IMP list
lock Showing 1 of 8 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Apixaban | 2 | Unknown | 2022-11-24 | 2023-08-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.